(Source: Datamonitor)
Enzon Pharmaceuticals has reported a net loss of $5.1 million, or $0.11 per diluted share, for the second quarter ended June 30, 2009, compared to a net loss of $1.74 million, or $0.04 per diluted share, for the second quarter of 2008.
For the second quarter of 2009, total revenues were $47.19 million, compared to $50.96 million in the second quarter of 2008. Operating loss was $3.45 million, compared to an operating income of $377,000 in the second quarter of 2008.
Jeffrey Buchalter, president and CEO of Enzon Pharmaceuticals, said: "We are pleased with the advancement of our innovative pipeline, particularly our novel PEG-SN38 compound, which is now enrolling patients in phase II. We have also made good progress in our next-generation Oncaspar program.
"The lifecycle sourcing programs are designed to improve the current versions of the marketed products and are required to continue to supply patients with these life-saving drugs."
A service of YellowBrix, Inc.
